New AI-generated COVID drug enters Phase I clinical trials: ‘Effective against all variants’
Fox News
Insilico Medicine recently announced that its new AI-designed drug for COVID-19 has entered Phase I clinical trials. If approved, it would become the first-ever alternative to Paxlovid.
This oral drug is a treatment, not a vaccine. If approved, it would become the first-ever alternative to Paxlovid, noted Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine. "Generative AI is transforming every area of human development." Melissa Rudy is health editor and a member of the lifestyle team at Fox News Digital.
"Generative AI is transforming every area of human development," said Zhavoronkov in a press release announcing the new discovery.
More Related News